Saphris gains indications

Merck announced that Saphris (asenapine sublingual tablets) has been approved for two additional indications: 1) the maintenance treatment of schizophrenia and 2) as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

LATUDA (lurasidone HCl) 40mg and 80mg tablets by Sunovion

Latuda approved for schizophrenia

The FDA has approved Latuda (lurasidone HCl tablets, from Sunovion), an oral once-daily atypical antipsychotic, for the treatment of schizophrenia in adults.